Top Markets
Coin of the day
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
주식 순위 #5110
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
주가
$58.70
마지막 동기화: 2024-01-23
시가총액
$2.98B
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Mirati Therapeutics, Inc. (MRTX)

카테고리

Mirati Therapeutics, Inc. (MRTX)의 주식 분할 이력
Mirati Therapeutics, Inc. 주식 (심볼: MRTX)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Aug 27, 2026에 발생했습니다.
Aug 27, 2026 이전에 매수한 MRTX 주식 1주는 현재 0주의 MRTX 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH